Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Belite Bio in a note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.48) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($1.91) EPS and FY2026 earnings at ($1.95) EPS.

A number of other analysts have also issued reports on the company. Benchmark restated a "buy" rating and issued a $80.00 target price on shares of Belite Bio in a report on Wednesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Belite Bio in a research note on Thursday.

Belite Bio Stock Performance

Shares of NASDAQ:BLTE opened at $64.40 on Monday. The stock has a fifty day moving average of $61.82 and a 200-day moving average of $63.03. The company has a market capitalization of $2.05 billion, a PE ratio of -58.02 and a beta of -1.48. Belite Bio has a one year low of $43.70 and a one year high of $86.53.

Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

Hedge Funds Weigh In On Belite Bio

Several hedge funds have recently bought and sold shares of BLTE. GAMMA Investing LLC grew its position in shares of Belite Bio by 43.3% in the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock valued at $122,000 after purchasing an additional 559 shares during the last quarter. Advisors Preferred LLC acquired a new stake in shares of Belite Bio in the fourth quarter valued at about $52,000. XTX Topco Ltd grew its position in shares of Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after purchasing an additional 1,668 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Belite Bio in the fourth quarter valued at about $155,000. Finally, Bank of America Corp DE grew its position in shares of Belite Bio by 36.4% in the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock valued at $1,157,000 after purchasing an additional 4,891 shares during the last quarter. 0.53% of the stock is owned by institutional investors and hedge funds.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.